Pharmaceuticals policy

Texas PBM Steerage Bill Becomes Law

Saturday, June 19, 2021 - 2:00pm

AUSTIN, Texas, June 19, 2021 /PRNewswire-PRWeb/ --In a significant victory for Texas pharmacists and their patients, Texas has enacted House Bill 1919, important legislation that protects community pharmacies and ensures patient choice by prohibiting pharmacy benefit managers (PBMs) from steering patients to pharmacies they own.

Key Points: 
  • AUSTIN, Texas, June 19, 2021 /PRNewswire-PRWeb/ --In a significant victory for Texas pharmacists and their patients, Texas has enacted House Bill 1919, important legislation that protects community pharmacies and ensures patient choice by prohibiting pharmacy benefit managers (PBMs) from steering patients to pharmacies they own.
  • The Texas Pharmacy Association (TPA) identified PBM reform as a top priority for the 87th Legislative Session and worked closely with legislators to enact meaningful legislation.
  • TPA is grateful to Texas legislators for recognizing that PBM practices shortchange pharmacists and create barriers, limiting access for patients to receive needed medications from their local pharmacy.
  • In May, Governor Abbott signed into law House Bill 1763, which improves patient access to needed prescription drugs while ensuring pharmacies are protected from PBM overreach.

AHF Files Federal Antitrust Lawsuit Against the PBM Prime Therapeutics

Friday, June 18, 2021 - 10:15pm

Prime is a pharmacy benefit manager (PBM), a middle-man in the distribution system for prescription drugs in the United States.

Key Points: 
  • Prime is a pharmacy benefit manager (PBM), a middle-man in the distribution system for prescription drugs in the United States.
  • Some of those people are patients of AHF pharmacies, and, in 2020, Prime processed almost 100,000 drug prescriptions for AHF patients.
  • In late 2019, Prime announced a new three-year collaboration with another PBM, Express Scripts, Inc.
  • In fact, it appears Prime is simply aligning its reimbursement rates with those of the other PBM, and doing so on an ongoing basis.

Global Antibiotics Active Pharmaceutical Ingredient (API) Market Forecast, Trend Analysis & Opportunity Assessment 2020-2030 - ResearchAndMarkets.com

Friday, June 18, 2021 - 4:27pm

The "Antibiotics Active Pharmaceutical Ingredient (API) Market Forecast, Trend Analysis & Opportunity Assessment 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antibiotics Active Pharmaceutical Ingredient (API) Market Forecast, Trend Analysis & Opportunity Assessment 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • A recent market study on the antibiotics API market offers global industry analysis for 2015-2019 & opportunity assessment for 2020-2030.
  • On conducting thorough research on the historical as well as current growth parameters of the antibiotics API market, growth prospects of the market are obtained with maximum precision.
  • This study on the antibiotics API market offers information divided into three important segments - API type, end user, and region.

2 Day Advanced Veterinary Pharmacovigilance Online Training Course, November 24th-25th, 2021 - ResearchAndMarkets.com

Friday, June 18, 2021 - 10:35am

The "Advanced Veterinary Pharmacovigilance Training Course" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Advanced Veterinary Pharmacovigilance Training Course" conference has been added to ResearchAndMarkets.com's offering.
  • The purpose of this seminar is to provide a comprehensive, yet practical, assessment of the main requirements of Volume IXB, the new key document on pharmacovigilance guidelines used by the veterinary regulatory authorities to ensure a compliant reporting company.
  • The programme will also consider the potential impact of Brexit on pharmacovigilance and the implications of the proposed EU Regulation (2019/6) on Veterinary Medicinal Products.
  • Interactive sessions throughout the two days will give delegates the opportunity to discuss key issues of current concern with our experienced trainer.

New Scamadviser Survey Find 28% of Consumers Would Consider Buying a Coronavirus Vaccine Online

Friday, June 18, 2021 - 8:00am

AMSTERDAM, June 18, 2021 /PRNewswire/ --Every year, Scamadviser analyzes the willingness of consumers to buy fake and counterfeit products online.

Key Points: 
  • AMSTERDAM, June 18, 2021 /PRNewswire/ --Every year, Scamadviser analyzes the willingness of consumers to buy fake and counterfeit products online.
  • While all income groups, educational categories, age levels, and continents are represented.Most consumers (65%) consider themselves capable of identifying fakes.
  • 40% of consumers doubt their ability to recognize fake medicines and toys while 24% say they have trouble with allcategories.
  • As an additional research question,Scamadviserthis year asked if the respondent would buy a coronavirus vaccine online.

Stakeholders Make Push for Pharmacy DIR Reform

Thursday, June 17, 2021 - 4:26pm

The Pharmacy DIR Reform to Reduce Senior Drug Costs Act (S. 1909 / H.R.

Key Points: 
  • The Pharmacy DIR Reform to Reduce Senior Drug Costs Act (S. 1909 / H.R.
  • Pharmacy DIR fee reform is urgently needed.
  • CMS has stated that eliminating retroactive pharmacy DIR fees will save beneficiaries an estimated $7.1-$9.2 billion in reduced cost sharing.
  • Today, billions of dollars in pharmacy DIR fees are assessed weeks, and sometimes months, after the point of sale.

Oregon Repeal of Unnecessary OTC Restrictions is a Dose of Good Policy for Consumers and Healthcare

Thursday, June 17, 2021 - 4:23pm

In a major victory for consumers, Oregon has repealed a 15-year-old law that banned OTC sales of certain medicines for colds and allergies containing PSE.

Key Points: 
  • In a major victory for consumers, Oregon has repealed a 15-year-old law that banned OTC sales of certain medicines for colds and allergies containing PSE.
  • The new Oregon law returns PSE to OTC status, allowing consumers to purchase 3.6 grams of PSE per day, up to 9 grams per month.
  • The Consumer Healthcare Products Association (CHPA) has long opposed restrictions on consumer access to Food and Drug Administration (FDA) approved OTC medicines.
  • Oregons Rx-only law for PSE was an unnecessary policy, so CHPA and numerous medical, consumer, and community stakeholders worked closely with Oregon lawmakers to change it.

Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer

Thursday, June 17, 2021 - 1:30pm

Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of December 16, 2021.

Key Points: 
  • Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of December 16, 2021.
  • When left undetected, recurrent or metastatic cervical cancer often develops, for which there are limited treatment options and a low chance of survival.
  • Current therapies for recurrent or metastatic cervical cancer are limited to a small subset of patients with limited benefit.
  • Balstilimab is currently in clinical trials as monotherapy and in combination with Agenus anti-CTLA-4, zalifrelimab, in an ongoing Phase 2 study for recurrent/metastatic cervical cancer.

Three Day Pharmacovigilance Training Course, June 21-23, 2021 - Basic Pharmacovigilance Principles and Terminologies Through to the Current Regulatory Framework

Thursday, June 17, 2021 - 1:30pm

DUBLIN, June 17, 2021 /PRNewswire/ -- The "Pharmacovigilance Training Course" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 17, 2021 /PRNewswire/ -- The "Pharmacovigilance Training Course" conference has been added to ResearchAndMarkets.com's offering.
  • This comprehensive three-day course has been designed to provide an introductory guide for all those concerned with pharmacovigilance.
  • The interactive programme will cover topics from basic pharmacovigilance principles and terminologies through to the current regulatory framework and its global impact, including drug surveillance in the EU, US and Japan.
  • Proactive pharmacovigilance pre- and post-marketing will be addressed as will risk management, the challenges of causality assessments, and effective signal detection.

OPTEL launches world's most powerful anticounterfeiting solution

Thursday, June 17, 2021 - 12:00pm

QUBEC CITY, June 17, 2021 /PRNewswire/ - OPTEL, a leading global provider of supply chain traceability technologies,today launched OPTEL IdentifAI, the most powerful product authentication solution on the market.

Key Points: 
  • QUBEC CITY, June 17, 2021 /PRNewswire/ - OPTEL, a leading global provider of supply chain traceability technologies,today launched OPTEL IdentifAI, the most powerful product authentication solution on the market.
  • "This is a game changer for both brands and consumers who want to protect themselves against product counterfeiting," said Florent Bouguin, Chief Technical Officer at OPTEL.
  • The result is a powerful brand-protection tool that can trace products from manufacturing to final consumer (or investigators).
  • OPTEL is a leading global provider of traceability systems and the initiator of SCALE AI, Canada's artificial intelligence-driven supply chain consortium.